A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2024-08-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24500
- Registration Number
- NCT04295005
- Locations
- ๐ฉ๐ช
Boehringer Ingelheim, Ingelheim am Rhein, Germany
Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;
Completed
- Conditions
- Stroke
- Interventions
- Drug: IV rtPA (intravenous recombinant plasminogen activator)
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 42188
- Registration Number
- NCT04290494
- Locations
- ๐จ๐ณ
Beijing Tiantan Hospital, Beijing, China
A Study in Healthy Men to Test How BI 1265162 is Taken up and Processed by the Body
Phase 1
Terminated
- Conditions
- Healthy Volunteers
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7
- Registration Number
- NCT04267276
- Locations
- ๐ณ๐ฑ
PRA Health Sciences Onderzoekscentrum Martini, Groningen, Netherlands
SITS-IVT in Patients >80 Years Study
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1655
- Registration Number
- NCT04260347
- Locations
- ๐ธ๐ช
Karolinska University Hospital, Stockholm, Sweden
A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 28
- Registration Number
- NCT04257032
- Locations
- ๐ฉ๐ช
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Early Intervention Efficacy in COPD
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Tiotropium/Olodaterol
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6788
- Registration Number
- NCT04249310
- Locations
- ๐ฏ๐ต
Nara Medical University, Nara, Japan
A Study to Test How Well Healthy Men and Women Tolerate Different Doses of BI 706321
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 39
- Registration Number
- NCT04241458
- Locations
- ๐ง๐ช
SGS Life Science Services - Clinical Research, Antwerpen, Belgium
A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 219
- Registration Number
- NCT04233801
- Locations
- ๐จ๐ณ
Peking University People's Hospital, Beijing, China
๐จ๐ณThe First Affiliated Hospital of Nanchang University, Nanchang, China
๐จ๐ณCentre Hospital of Putuo District, Shanghai, Shanghai, China
A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body
Phase 1
Terminated
- Conditions
- Healthy
- Interventions
- Drug: BI 894416 Reference FormulationDrug: BI 894416 Formulation A2Drug: BI 894416 Formulation C2Drug: BI 894416 Formulation D2Drug: BI 894416 Formulation F2
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT04232839
- Locations
- ๐ฌ๐ง
Quotient Sciences, Nottingham, United Kingdom
A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimatยฎ Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 213
- Registration Number
- NCT04223843
- Locations
- ๐บ๐ธ
Meris Clinical Research, Brandon, Florida, United States
๐บ๐ธClinical Research Specialists LLC, Kissimmee, Florida, United States
๐ฉ๐ชKlinische Forschung Berlin GbR, Berlin, Germany
ยฉ Copyright 2025. All Rights Reserved by MedPath